These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 26812210)
1. Monitoring Ligand-Induced Protein Ordering in Drug Discovery. Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210 [TBL] [Abstract][Full Text] [Related]
2. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571 [TBL] [Abstract][Full Text] [Related]
3. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor. Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499 [TBL] [Abstract][Full Text] [Related]
4. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352 [TBL] [Abstract][Full Text] [Related]
5. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells. Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697 [TBL] [Abstract][Full Text] [Related]
6. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179 [TBL] [Abstract][Full Text] [Related]
7. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction. Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444 [TBL] [Abstract][Full Text] [Related]
8. Hydrogen Bond Dynamic Propensity Studies for Protein Binding and Drug Design. Menéndez CA; Accordino SR; Gerbino DC; Appignanesi GA PLoS One; 2016; 11(10):e0165767. PubMed ID: 27792778 [TBL] [Abstract][Full Text] [Related]
9. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors. Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721 [TBL] [Abstract][Full Text] [Related]
11. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450 [TBL] [Abstract][Full Text] [Related]
12. Molecular basis for the inhibition of p53 by Mdmx. Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582 [TBL] [Abstract][Full Text] [Related]
13. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534 [TBL] [Abstract][Full Text] [Related]
14. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction. Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609 [TBL] [Abstract][Full Text] [Related]
15. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207 [TBL] [Abstract][Full Text] [Related]
16. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers. Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147 [TBL] [Abstract][Full Text] [Related]
17. Inhibitors of MDM2 and MDMX: a structural perspective. Riedinger C; McDonnell JM Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792 [TBL] [Abstract][Full Text] [Related]
19. Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry. Hernychova L; Man P; Verma C; Nicholson J; Sharma CA; Ruckova E; Teo JY; Ball K; Vojtesek B; Hupp TR Proteomics; 2013 Aug; 13(16):2512-25. PubMed ID: 23776060 [TBL] [Abstract][Full Text] [Related]
20. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]